EMPACT-MI: Another SGLT2 Inhibitor Miss Post-MI EMPACT-MI: Another SGLT2 Inhibitor Miss Post-MI

Empagliflozin added to standard care did not improve outcomes in post-MI patients at risk for heart failure. John Mandrola, MD, sees the diminishing returns for add-on drugs as positive for patients.theheart.org on Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Commentary Source Type: news